Insmed Deferred Long Term Liab vs Long Term Debt Total Analysis
INSM Stock | USD 69.61 1.06 1.50% |
Insmed financial indicator trend analysis is infinitely more than just investigating Insmed Inc recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Insmed Inc is a good investment. Please check the relationship between Insmed Deferred Long Term Liab and its Long Term Debt Total accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Insmed Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.
Deferred Long Term Liab vs Long Term Debt Total
Deferred Long Term Liab vs Long Term Debt Total Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Insmed Inc Deferred Long Term Liab account and Long Term Debt Total. At this time, the significance of the direction appears to have very week relationship.
The correlation between Insmed's Deferred Long Term Liab and Long Term Debt Total is 0.25. Overlapping area represents the amount of variation of Deferred Long Term Liab that can explain the historical movement of Long Term Debt Total in the same time period over historical financial statements of Insmed Inc, assuming nothing else is changed. The correlation between historical values of Insmed's Deferred Long Term Liab and Long Term Debt Total is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Deferred Long Term Liab of Insmed Inc are associated (or correlated) with its Long Term Debt Total. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Long Term Debt Total has no effect on the direction of Deferred Long Term Liab i.e., Insmed's Deferred Long Term Liab and Long Term Debt Total go up and down completely randomly.
Correlation Coefficient | 0.25 |
Relationship Direction | Positive |
Relationship Strength | Very Weak |
Deferred Long Term Liab
Liabilities that are due after more than one year, including deferred tax liabilities and deferred revenue.Long Term Debt Total
Most indicators from Insmed's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Insmed Inc current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Insmed Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. At this time, Insmed's Selling General Administrative is very stable compared to the past year. As of the 29th of December 2024, Tax Provision is likely to grow to about 2.7 M, while Issuance Of Capital Stock is likely to drop about 250.4 M.
Insmed fundamental ratios Correlations
Click cells to compare fundamentals
Insmed Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Insmed fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 742.3M | 796.2M | 1.2B | 1.7B | 1.3B | 1.4B | |
Other Current Liab | 280K | 50.8M | 79.1M | 131.7M | 149.6M | 157.1M | |
Total Current Liabilities | 85.2M | 118.8M | 135.2M | 190.2M | 225.6M | 236.9M | |
Total Stockholder Equity | 261.7M | 275.9M | 410.5M | 88.0M | (331.9M) | (315.3M) | |
Property Plant And Equipment Net | 113.1M | 97.2M | 95.5M | 102.1M | 104.4M | 109.6M | |
Net Debt | (90.4M) | (127.9M) | (104.5M) | 103.8M | 721.6M | 757.7M | |
Retained Earnings | (1.5B) | (1.8B) | (2.3B) | (2.7B) | (3.4B) | (3.3B) | |
Accounts Payable | 13.2M | 42.9M | 35.8M | 50.5M | 65.4M | 68.7M | |
Cash | 487.4M | 532.8M | 716.8M | 1.1B | 482.4M | 506.5M | |
Non Current Assets Total | 187.1M | 173.3M | 406.5M | 383.1M | 400.8M | 420.8M | |
Non Currrent Assets Other | 20.3M | 26.8M | 51.0M | 76.1M | 96.6M | 101.4M | |
Cash And Short Term Investments | 487.4M | 532.8M | 716.8M | 1.1B | 780.4M | 819.5M | |
Common Stock Total Equity | 897K | 1.0M | 1.2M | 1.4M | 1.6M | 804.3K | |
Common Stock Shares Outstanding | 84.6M | 97.6M | 112.1M | 123.0M | 140.4M | 147.5M | |
Liabilities And Stockholders Equity | 742.3M | 796.2M | 1.2B | 1.7B | 1.3B | 1.4B | |
Other Current Assets | 20.2M | 48.0M | 57.8M | 25.5M | 24.2M | 25.4M | |
Other Stockholder Equity | 1.8B | 2.1B | 2.7B | 2.8B | 3.1B | 3.3B | |
Total Liab | 480.6M | 520.3M | 833.0M | 1.6B | 1.7B | 1.7B | |
Property Plant And Equipment Gross | 113.1M | 97.2M | 95.5M | 102.1M | 149.0M | 156.5M | |
Total Current Assets | 555.2M | 622.9M | 837.0M | 1.3B | 929.1M | 975.5M | |
Accumulated Other Comprehensive Income | (10K) | 193K | 968K | 756K | (745K) | (782.3K) | |
Common Stock | 897K | 1.0M | 1.2M | 1.4M | 1.5M | 837.2K | |
Other Assets | 72.5M | 70.0M | 51.0M | 113.7M | 130.7M | 137.3M | |
Good Will | 58.7M | 53.7M | 49.3M | 136.1M | 156.5M | 164.4M | |
Non Current Liabilities Total | 395.4M | 401.5M | 697.9M | 1.4B | 1.4B | 1.5B | |
Intangible Assets | 53.7M | 49.3M | 73.8M | 68.8M | 63.7M | 61.3M | |
Property Plant Equipment | 60.2M | 54.0M | 53.0M | 56.5M | 65.0M | 68.2M | |
Net Receivables | 19.2M | 16.6M | 24.4M | 29.7M | 41.2M | 43.2M | |
Short Long Term Debt Total | 397.0M | 404.8M | 612.3M | 1.2B | 1.2B | 1.3B | |
Long Term Debt | 335.9M | 356.3M | 566.6M | 1.1B | 1.2B | 1.2B | |
Inventory | 28.3M | 49.6M | 67.0M | 69.9M | 83.2M | 87.4M | |
Net Tangible Assets | 208.0M | 226.6M | 200.5M | (116.9M) | (134.5M) | (127.7M) | |
Retained Earnings Total Equity | (1.5B) | (1.8B) | (2.3B) | (2.7B) | (2.4B) | (2.3B) | |
Capital Surpluse | 1.8B | 2.1B | 2.7B | 2.8B | 3.2B | 3.4B | |
Deferred Long Term Liab | 52.1M | 47.3M | 72.0M | 37.6M | 43.2M | 45.7M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Insmed Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Insmed. If investors know Insmed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Insmed listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.55) | Revenue Per Share 2.206 | Quarterly Revenue Growth 0.182 | Return On Assets (0.26) | Return On Equity (8.91) |
The market value of Insmed Inc is measured differently than its book value, which is the value of Insmed that is recorded on the company's balance sheet. Investors also form their own opinion of Insmed's value that differs from its market value or its book value, called intrinsic value, which is Insmed's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Insmed's market value can be influenced by many factors that don't directly affect Insmed's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Insmed's value and its price as these two are different measures arrived at by different means. Investors typically determine if Insmed is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Insmed's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.